BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 210 filers reported holding BRIDGEBIO PHARMA INC in Q2 2023. The put-call ratio across all filers is 0.74 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $6,124,287 | -7.8% | 241,780 | +12.6% | 0.00% | 0.0% |
| Q1 2024 | $6,641,678 | +81.3% | 214,802 | +136.7% | 0.00% | +50.0% |
| Q4 2023 | $3,664,102 | -70.2% | 90,763 | -80.5% | 0.00% | -66.7% |
| Q3 2023 | $12,289,844 | +136.1% | 466,054 | +54.0% | 0.01% | +100.0% |
| Q2 2023 | $5,206,440 | +75873.2% | 302,700 | -26.8% | 0.00% | -25.0% |
| Q1 2023 | $6,853 | +969.1% | 413,369 | +391.1% | 0.00% | – |
| Q4 2022 | $641 | -100.0% | 84,177 | -92.8% | 0.00% | -100.0% |
| Q3 2022 | $11,583,000 | +111.9% | 1,165,308 | +93.6% | 0.01% | +133.3% |
| Q2 2022 | $5,465,000 | -47.1% | 601,867 | -40.9% | 0.00% | -50.0% |
| Q1 2022 | $10,331,000 | -60.7% | 1,017,809 | -35.4% | 0.01% | -57.1% |
| Q4 2021 | $26,289,000 | +136.5% | 1,576,073 | +564.4% | 0.01% | +100.0% |
| Q3 2021 | $11,118,000 | +29.3% | 237,215 | +68.2% | 0.01% | +40.0% |
| Q2 2021 | $8,596,000 | +233.6% | 141,011 | +237.0% | 0.01% | +150.0% |
| Q1 2021 | $2,577,000 | -64.3% | 41,842 | -58.8% | 0.00% | -60.0% |
| Q4 2020 | $7,214,000 | +457.5% | 101,442 | +155.7% | 0.01% | +150.0% |
| Q2 2020 | $1,294,000 | -81.1% | 39,680 | -83.2% | 0.00% | -86.7% |
| Q1 2020 | $6,850,000 | +754.1% | 236,200 | +531.9% | 0.02% | +1400.0% |
| Q3 2019 | $802,000 | -92.2% | 37,382 | -90.2% | 0.00% | -93.3% |
| Q2 2019 | $10,246,000 | – | 379,919 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 6,068,125 | $153,705,606 | 66.52% |
| Kohlberg Kravis Roberts & Co. L.P. | 31,060,971 | $786,774,395 | 23.60% |
| SUPERSTRING CAPITAL MANAGEMENT LP | 219,837 | $5,568,471 | 7.02% |
| Prosight Management, LP | 800,000 | $20,264,000 | 6.06% |
| ADAR1 Capital Management, LLC | 1,264,570 | $32,031,558 | 6.05% |
| Frazier Life Sciences Management, L.P. | 3,632,604 | $92,013,859 | 4.30% |
| M28 Capital Management LP | 121,200 | $3,069,996 | 3.98% |
| SPHERA FUNDS MANAGEMENT LTD. | 910,070 | $23,052,073 | 3.14% |
| Octagon Capital Advisors LP | 690,000 | $17,477,700 | 2.75% |
| Cormorant Asset Management, LP | 1,858,351 | $47,072,031 | 2.72% |